How AbbVie stitched its latest patent thicket
AbbVie, famous for the bramble of intellectual property that has kept Humira lucrative after nearly 20 years, appears to be replicating the process for a top-selling cancer drug.
As STAT’s Ed Silverman reports, AbbVie has filed dozens of patents related to Imbruvica, a drug first approved in 2013. The drug’s key patent is set to expire in 2026, but AbbVie’s latest claims would keep generic competition off the market until 10 years later, according to the analysis by the nonprofit Initiative for Medicines, Access, and Knowledge, maintaining the company’s monopoly on a drug that costs $174,000 a year.
“This is AbbVie’s playbook,” said Tahir Amin, the executive director of the nonprofit. “It’s in line with their behavior with Humira, where most of the patents were filed after the first approval. Once the drug is approved, they try to extend patent life as much as possible.”
Read more.
As STAT’s Ed Silverman reports, AbbVie has filed dozens of patents related to Imbruvica, a drug first approved in 2013. The drug’s key patent is set to expire in 2026, but AbbVie’s latest claims would keep generic competition off the market until 10 years later, according to the analysis by the nonprofit Initiative for Medicines, Access, and Knowledge, maintaining the company’s monopoly on a drug that costs $174,000 a year.
“This is AbbVie’s playbook,” said Tahir Amin, the executive director of the nonprofit. “It’s in line with their behavior with Humira, where most of the patents were filed after the first approval. Once the drug is approved, they try to extend patent life as much as possible.”
Read more.
No hay comentarios:
Publicar un comentario